Tag Archives: China

Behind the China Bribery Scandals

The last few weeks have seen the media swamped with stories about the rampant bribery clawing the pharmaceutical industry in China. Big names were engulfed in the scandal, including GSK, AstraZeneca, Sanofi, Novartis, Eli Lilly, Novo Nordisk and UCB amongst others. Last month, four GSK executives were put under investigation for allegedly paying up to […]
Posted in Emerging Markets, Global, Guest Blog | Also tagged , , , , , , , , | Leave a comment

One Company, One Defining Moment

Being an observer rather than a participant in the drugs business makes it easier to sense those defining moments when something fundamental has changed, a limit is reached, and a new order emerges to reset the basic license to operate.   As Pharm Exec monthly goes to press, one such moment appears to have arrived, with […]
Posted in Emerging Markets, Global, Strategy | Also tagged , , , , , , , | 1 Comment

Breaching the Great Wall: Major Pharma Changes Proposed in China

With a revision of China’s basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation. Dr. Wang Chenguang, Dean of Tsinghua Law School Behind the vaulting growth statistics that make China the centerfold in Big Pharma’s global playbook is a […]
Posted in compliance, Emerging Markets, Global, IP, R&D, Regulatory | Also tagged , , , , , , , , , | 3 Comments

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.  Here’s a list of six that Pharm Exec thinks are most important:
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, pricing, Strategy | Also tagged , , , , , , , | 6 Comments

R&D Trends for 2013: Data Trims, Partnerships, and Emerging Global Players

The Tufts Center for the Study of Drug Development (CSDD) sees two key trends as increasingly important for pharmaceutical companies to maintain success: eliminating the bane of extraneous data and fostering collaborations with academia and multi-company consortia both as measures of reducing costs and remaining competitive by more quickly and effectively guiding medicines to market. […]
Posted in Emerging Markets, IP, R&D, Strategy | Also tagged , | 1 Comment
  • Categories

  • Meta